Kevin Weil Launches Warp Sciences with $215M for AI-Driven Drug Development

• Kevin Weil, former head of science at OpenAI, launches Warp Sciences with $215M investment.
• Warp Sciences aims to automate a key step in drug development using AI, reducing reliance on Chinese firms.
• The startup is valued at $865M and is led by Lightspeed Venture Partners.
• Warp Sciences plans to build an automated lab in the US to handle the outsourced drug development step.
• The initiative seeks to address the long-standing practice of outsourcing this step to companies like WuXi AppTec.